The earnings call highlighted strong revenue growth and new product approval, indicating positive market momentum. However, challenges such as the drug shortage and declining Trogarzo sales were significant concerns. The company's strategic focus on transitioning to the new product formulation and managing operational efficiencies shows resilience.

Company Guidance -

Q3 2025

During the Theratechnologies first quarter 2025 earnings call, the company reported total revenues of $19 million, reflecting a 17% growth from the same period last year. This growth was primarily driven by their lead asset, EGRIFTA SV, which experienced strong momentum in the market. Despite a temporary drug shortage that impacted sales for six to seven weeks, new enrollments were up by 15% compared to the previous year. The company's adjusted EBITDA for the quarter was positive at $2.3 million, a significant improvement from a loss of $247,000 in the same period last year. Theratechnologies provided guidance for 2025, expecting revenues between $80 million and $83 million and adjusted EBITDA ranging from $10 million to $12 million. The approval of their new F8 Formulation of Tesamorelin is anticipated to further bolster growth, with a planned transition from EGRIFTA SV to EGRIFTA WR to be completed by early 2026.

Revenue Growth

Theratechnologies reported total revenues of $19 million for the fiscal first quarter, representing a 17% growth from the same period last year. The growth was primarily driven by EGRIFTA SV.

New Product Approval

The company received approval for the F8 Formulation of Tesamorelin, which only requires once-weekly reconstitution, a significant improvement over the previous daily requirement.

Increased Patient Enrollment

New enrollments were up 15% in the first quarter compared to last year, indicating strong market demand and effective sales strategies.

Adjusted EBITDA Improvement

The company reported a positive adjusted EBITDA of $2.3 million versus an adjusted EBITDA loss of $247,000 last year.

HIV Business Data Presentation

Data from the PROMISE-U.S. and VAMOS studies were presented, showcasing the efficacy and safety of ibalizumab in reducing HIV to undetectable levels in heavily treatment-experienced patients.

Theratechnologies (THTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

THTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 09, 2025	2025 (Q3)	0.01 / -	0.06	―	―	―
Jul 09, 2025	2025 (Q2)	-0.01 / -0.09	0.02	-550.00% (-0.11)	―	―
Apr 09, 2025	2025 (Q1)	0.03 / 0.00	-0.1	―	―
Feb 26, 2025	2024 (Q4)	0.05 / -0.16	-0.08	-100.00% (-0.08)	―
Oct 10, 2024	2024 (Q3)	0.03 / 0.06	-0.03	300.00% (+0.09)	―
Jul 10, 2024	2024 (Q2)	-0.02 / 0.02	-0.405	104.94% (+0.43)	―
Apr 10, 2024	2024 (Q1)	-0.12 / -0.10	-0.44	77.27% (+0.34)	―
Feb 21, 2024	2023 (Q4)	-0.31 / -0.08	-0.36	77.78% (+0.28)	―
Sep 26, 2023	2023 (Q3)	-0.29 / -0.03	-0.32	90.63% (+0.29)	―
Jul 12, 2023	2023 (Q2)	-0.25 / -0.41	-0.96	57.81% (+0.55)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

THTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 09, 2025	$3.14	$3.14	0.00%
Apr 09, 2025	$1.55	$1.42	-8.39%
Feb 26, 2025	$1.82	$1.60	-12.09%
Oct 10, 2024	$1.22	$1.26	+3.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Theratechnologies Inc (THTX) report earnings?

Theratechnologies Inc (THTX) is schdueled to report earning on Oct 09, 2025, TBA (Confirmed).

What is Theratechnologies Inc (THTX) earnings time?

Theratechnologies Inc (THTX) earnings time is at Oct 09, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is THTX EPS forecast?

THTX EPS forecast for the fiscal quarter 2025 (Q3) is 0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing